MiR-155 and MiR-1275 relation with graft-versus-host disease and hepatitis B in hematopoietic stem cell transplant recipients

miR-155 和 miR-1275 与造血干细胞移植受者移植物抗宿主病和乙型肝炎的关系

阅读:1

Abstract

INTRODUCTION: MicroRNAs (miRNAs) play many roles in basic biological processes such as virus proliferation and growth. In this research, we sought to investigate the prognostic and diagnostic potential of miR-155 and miR-1275 in the induction and severity of Graft-Versus-Host Disease (aGVHD) following hematopoietic stem cell transplantation (HSCT). Additionally, we evaluated the association between these miRNAs' expression and HBV infection in patients with HSCT. METHOD: In the present research, 135 consecutive patients receiving allogeneic HSCT were enrolled. We assessed the expression levels of miR-155 and miR-1275 in the peripheral blood of patients before and after HSCT by SYBR Green Real-Time PCR. In these patients Hepatitis B virus (HBV) load was also determined by HBV antibody assay. RESULTS: MiR-1275 and miR-155 expression levels were significantly lower in patients after HSCT. A significant association was found between miR-155 and miR-1275 expression levels in patients who developed aGvHD compared with those without aGvHD. We also found that only MiR-155 expression level was significantly increased in HBV + patients compared with HBV- patients. CONCLUSION: Both MiR-1275 and miR-155 genes have the potential to be used as therapeutic targets in HSCT patients in the future. The expression level of both could be employed as biomarkers for aGvHD induction. Moreover, MiR-155 expression level was connected to the pathogenesis of HBV infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。